Breaking Update
Israeli AI Firm CytoReason Expands Drug Discovery Partnership With France’s Sanofi
Israeli AI firm CytoReason expands drug discovery partnership with Sanofi in a new multi-year agreement valued up to $16 million, marking its fifth commercial.
Jerusalem, 11 January, 2026 (TPS-IL) — Israeli AI-driven drug discovery company CytoReason has expanded its collaboration with French pharmaceutical giant Sanofi for the third time, under a new multi-year agreement valued at up to $16 million. Announced from Tel Aviv, the deal marks CytoReason’s fifth commercial agreement of 2025 and further strengthens its growing footprint among global pharma leaders.
CytoReason’s technology uses advanced computational disease models to help R&D teams extract actionable insights from molecular and clinical data, accelerating decision-making across drug development programs. The company, backed by U.S.-based investors including NVIDIA, Thermo Fisher Scientific, and Pfizer, works with roughly half of the world’s top 20 pharmaceutical companies.
